探讨特布他林与布地奈德雾化吸入治疗慢支合并肺气肿的临床疗效及安全性(1)
[摘要] 目的 觀察特布他林与布地奈德雾化吸入治疗慢支合并肺气肿的的效果及其安全性。 方法 研究时间以2016年9月—2018年9月为准，根据随机数表法对66例慢支肺气肿患者分为两组进行治疗。对照组接受常规综合治疗，观察组基于此联合特布地林和布地奈德雾化吸入治疗。对比两组治疗效果，并就治疗前后患者肺功能各项指标变化情况，治疗期间不良反应事件作对比。 结果 从疗效上来看，观察组治疗总有效率为96.97%，明显优于对照组的81.82%，差异有统计学意义(χ2=3.995 2，P<0.05)。治疗前，各组肺功能指标比较均差异无统计学意义(t=0.155 8、0.517 5、0.129 0，P>0.05);治疗后，观察组患者FEV1(3.37±0.31)L、FVC(4.07±0.78)L、FEV1/FVC(83.44±13.41)%较治疗前有显著改善(t=22.104 7、4.327 5、5.012 1)，且显著优于对照组FEV1(2.55±0.18)L、FVC(3.65±0.62)L、FEV1/FVC(70.15±15.23)%，差异有统计学意义(t=11.828 2、2.421 4、3.762 3，P<0.05)。观察组不良反应发生率为9.10%，与对照组的6.06%对比并差异无统计学意义(P>0.05)。 结论 针对慢支肺气肿患者可在常规综合治疗基础上联合使用特布他林与布地奈德雾化吸入，以帮助快速改善患者肺功能，减轻痛苦，且安全性高，疗效更好，值得推广。
[关键词] 特布他林;布地奈德;慢支肺气肿;安全性
[中图分类号] R562.2+1;R563.3 [文献标识码] A [文章编号] 1674-0742(2019)09(b)-0117-03
Investigation on the Clinical Efficacy and Safety of Terbutaline and Budesonide Inhalation in the Treatment of Chronic Bronchitis Complicated with Emphysema
GU Yun-biao
Department of Internal Medicine， Qidong Third People's Hospital， Qidong， Jiangsu Province， 226200 China
[Abstract] Objective To observe the efficacy and safety of terbutaline and budesonide in the treatment of chronic bronchitis with emphysema. Methods The research period is from September 2016 to September 2018. 66 patients with chronic emphysema who were conveniently selected into the study were divided into two groups according to the random number table method. The control group received conventional comprehensive treatment， and the observation group was based on this combined with terbutaline and budesonide for inhalation therapy. The therapeutic effects of the two groups were compared， and the changes of lung function indexes before and after treatment were compared with the adverse reaction events during the treatment. Results From the therapeutic effect， the total effective rate of the observation group was 96.97%， which was significantly better than 81.82% of the control group，the difference was statistically significant(χ2=3.995 2， P<0.05). Before treatment， there was no significant difference in lung function indexes between the groups(t=0.155 8，0.517 5，0.129 0，P>0.05). After treatment， the patients in the observation group had FEV1 (3.37±0.31) L and FVC (4.07±0.78) L， FEV1/FVC (83.44±13.41)% was significantly improved compared with before treatment (t=22.104 7，4.327 5、5.012 1)， and significantly better than the control group FEV1 (2.55 ± 0.18) L， FVC (3.65±0.62)L， FEV1/FVC (70.15±15.23)%，the difference was statistically significant(t=11.828 2，2.421 4，3.762 3，P<0.05). The incidence of adverse reactions was 9.10% in the observation group， and there was no statistically significant difference compared with 6.06% in the control group (P>0.05). Conclusion For patients with chronic emphysema， terbutaline and bude can be combined with conventional comprehensive treatment to help improve lung function and relieve pain， and it is safe and effective. It is worth promoting., 百拇医药(顾云飚)
[关键词] 特布他林;布地奈德;慢支肺气肿;安全性
[中图分类号] R562.2+1;R563.3 [文献标识码] A [文章编号] 1674-0742(2019)09(b)-0117-03
Investigation on the Clinical Efficacy and Safety of Terbutaline and Budesonide Inhalation in the Treatment of Chronic Bronchitis Complicated with Emphysema
GU Yun-biao
Department of Internal Medicine， Qidong Third People's Hospital， Qidong， Jiangsu Province， 226200 China
[Abstract] Objective To observe the efficacy and safety of terbutaline and budesonide in the treatment of chronic bronchitis with emphysema. Methods The research period is from September 2016 to September 2018. 66 patients with chronic emphysema who were conveniently selected into the study were divided into two groups according to the random number table method. The control group received conventional comprehensive treatment， and the observation group was based on this combined with terbutaline and budesonide for inhalation therapy. The therapeutic effects of the two groups were compared， and the changes of lung function indexes before and after treatment were compared with the adverse reaction events during the treatment. Results From the therapeutic effect， the total effective rate of the observation group was 96.97%， which was significantly better than 81.82% of the control group，the difference was statistically significant(χ2=3.995 2， P<0.05). Before treatment， there was no significant difference in lung function indexes between the groups(t=0.155 8，0.517 5，0.129 0，P>0.05). After treatment， the patients in the observation group had FEV1 (3.37±0.31) L and FVC (4.07±0.78) L， FEV1/FVC (83.44±13.41)% was significantly improved compared with before treatment (t=22.104 7，4.327 5、5.012 1)， and significantly better than the control group FEV1 (2.55 ± 0.18) L， FVC (3.65±0.62)L， FEV1/FVC (70.15±15.23)%，the difference was statistically significant(t=11.828 2，2.421 4，3.762 3，P<0.05). The incidence of adverse reactions was 9.10% in the observation group， and there was no statistically significant difference compared with 6.06% in the control group (P>0.05). Conclusion For patients with chronic emphysema， terbutaline and bude can be combined with conventional comprehensive treatment to help improve lung function and relieve pain， and it is safe and effective. It is worth promoting., 百拇医药(顾云飚)